Literature DB >> 18205204

Clinical and molecular features of mitochondrial DNA depletion due to mutations in deoxyguanosine kinase.

D P Dimmock1, Q Zhang, C Dionisi-Vici, R Carrozzo, J Shieh, L-Y Tang, C Truong, E Schmitt, M Sifry-Platt, S Lucioli, F M Santorelli, C H Ficicioglu, M Rodriguez, K Wierenga, G M Enns, N Longo, M H Lipson, H Vallance, W J Craigen, F Scaglia, L-J Wong.   

Abstract

Published mutations in deoxyguanosine kinase (DGUOK) cause mitochondrial DNA depletion and a clinical phenotype that consists of neonatal liver failure, nystagmus and hypotonia. In this series, we have identified 15 different mutations in the DGUOK gene from 9 kindreds. Among them, 12 have not previously been reported. Nonsense, splice site, or frame-shift mutations that produce truncated proteins predominate over missense mutations. All patients who harbor null mutations had early onset liver failure and significant neurological disease. These patients have all died before 2-years of age. Conversely, two patients carrying missense mutations had isolated liver disease and are alive in their 4th year of life without liver transplant. Five subjects were detected by newborn screening, with elevated tyrosine or phenylalanine. Consequently, this disease should be considered if elevated tyrosine is identified by newborn screening. Mitochondrial DNA content was below 10% of controls in liver in all but one case and modestly reduced in blood cells. With this paper a total of 39 different mutations in DGUOK have been identified. The most frequent mutation, c.763_c.766dupGATT, occurs in 8 unrelated kindreds. 70% of mutations occur in only one kindred, suggesting full sequencing of this gene is required for diagnosis. The presentation of one case with apparent viral hepatitis, without neurological disease, suggests that this disease should be considered in patients with infantile liver failure regardless of the presence of neurological features or apparent infectious etiology. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18205204     DOI: 10.1002/humu.9519

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  39 in total

1.  Two patients with hepatic mtDNA depletion syndromes and marked elevations of S-adenosylmethionine and methionine.

Authors:  S Harvey Mudd; Conrad Wagner; Zigmund Luka; Sally P Stabler; Robert H Allen; Richard Schroer; Timothy Wood; Jing Wang; Lee-Jun Wong
Journal:  Mol Genet Metab       Date:  2011-11-12       Impact factor: 4.797

2.  Potentially diagnostic electron paramagnetic resonance spectra elucidate the underlying mechanism of mitochondrial dysfunction in the deoxyguanosine kinase deficient rat model of a genetic mitochondrial DNA depletion syndrome.

Authors:  Brian Bennett; Daniel Helbling; Hui Meng; Jason Jarzembowski; Aron M Geurts; Marisa W Friederich; Johan L K Van Hove; Michael W Lawlor; David P Dimmock
Journal:  Free Radic Biol Med       Date:  2016-01-08       Impact factor: 7.376

3.  Quantitative Analysis of mtDNA Content in Formalin-Fixed Paraffin-Embedded Muscle Tissue.

Authors:  Aida Font; Frederic Tort; Aleix Navarro-Sastre; Victòria Cusí; Judit García-Villoria; Paz Briones; Antonia Ribes
Journal:  JIMD Rep       Date:  2011-06-22

4.  Mitochondrial respiratory chain hepatopathies: role of liver transplantation. A case series of five patients.

Authors:  Elisabeth De Greef; John Christodoulou; Ian E Alexander; Albert Shun; Edward V O'Loughlin; David R Thorburn; Vicki Jermyn; Michael O Stormon
Journal:  JIMD Rep       Date:  2011-11-04

5.  Neonatal liver failure due to deoxyguanosine kinase deficiency.

Authors:  Susana Nobre; Manuela Grazina; Francisco Silva; Carla Pinto; Isabel Gonçalves; Luísa Diogo
Journal:  BMJ Case Rep       Date:  2012-04-02

6.  Mitochondrial DNA Depletion and Deletions in Paediatric Patients with Neuromuscular Diseases: Novel Phenotypes.

Authors:  Tuomas Komulainen; Milla-Riikka Hautakangas; Reetta Hinttala; Salla Pakanen; Vesa Vähäsarja; Petri Lehenkari; Päivi Olsen; Päivi Vieira; Outi Saarenpää-Heikkilä; Johanna Palmio; Hannu Tuominen; Pietari Kinnunen; Kari Majamaa; Heikki Rantala; Johanna Uusimaa
Journal:  JIMD Rep       Date:  2015-05-05

7.  Renal manifestations of primary mitochondrial disorders.

Authors:  Josef Finsterer; Fulvio Alexandre Scorza
Journal:  Biomed Rep       Date:  2017-04-12

Review 8.  Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options.

Authors:  Ayman W El-Hattab; Fernando Scaglia
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 9.  Gastrointestinal and hepatic manifestations of mitochondrial disorders.

Authors:  Shamima Rahman
Journal:  J Inherit Metab Dis       Date:  2013-05-15       Impact factor: 4.982

10.  Administration of deoxyribonucleosides or inhibition of their catabolism as a pharmacological approach for mitochondrial DNA depletion syndrome.

Authors:  Yolanda Cámara; Emiliano González-Vioque; Mauro Scarpelli; Javier Torres-Torronteras; Andrea Caballero; Michio Hirano; Ramon Martí
Journal:  Hum Mol Genet       Date:  2013-12-20       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.